Celcuity posts better-than-expected Q4 adjusted net loss

Celcuity

25/03/2026 20:16

Overview

U.S. biotech firm's Q4 adjusted EPS comes in better than expectations

Adjusted net loss for Q4 also comes in better than analyst expectations

Outlook

Celcuity expects topline results from PIK3CA mutant cohort in Q2 2026

Company preparing for potential commercial launch of gedatolisib in Q3 2026

Result Drivers

R&D AND LAUNCH COSTS - Higher Q4 operating expenses driven by increased R&D and commercial launch-related activities

HIGHER G&A EXPENSES - Increase in G&A expenses mainly due to higher employee-related and consulting costs, including non-cash stock-based compensation

Company press release: ID:nGNX65pryF

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
-$0.73
-$1.04 (10 Analysts)
Q4 EPS
-$0.97
Q4 Adjusted Net Income
Beat
-$38.4 mln
-$47.76 mln (9 Analysts)
Q4 Net Income
-$51 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Celcuity Inc is $120.00, about 17.6% above its March 24 closing price of $102.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)